• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

围手术期保护肾功能的干预措施。

Interventions for protecting renal function in the perioperative period.

作者信息

Zacharias Mathew, Mugawar Mohan, Herbison G Peter, Walker Robert J, Hovhannisyan Karen, Sivalingam Pal, Conlon Niamh P

机构信息

Department of Anaesthesia & Intensive Care, Dunedin Hospital, Great King Street, Dunedin, New Zealand, Private Bag 192.

出版信息

Cochrane Database Syst Rev. 2013 Sep 11;2013(9):CD003590. doi: 10.1002/14651858.CD003590.pub4.

DOI:10.1002/14651858.CD003590.pub4
PMID:24027097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7154582/
Abstract

BACKGROUND

Various methods have been used to try to protect kidney function in patients undergoing surgery. These most often include pharmacological interventions such as dopamine and its analogues, diuretics, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, N-acetyl cysteine (NAC), atrial natriuretic peptide (ANP), sodium bicarbonate, antioxidants and erythropoietin (EPO).

OBJECTIVES

This review is aimed at determining the effectiveness of various measures advocated to protect patients' kidneys during the perioperative period.We considered the following questions: (1) Are any specific measures known to protect kidney function during the perioperative period? (2) Of measures used to protect the kidneys during the perioperative period, does any one method appear to be more effective than the others? (3) Of measures used to protect the kidneys during the perioperative period,does any one method appear to be safer than the others?

SEARCH METHODS

In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 2, 2012), MEDLINE (Ovid SP) (1966 to August 2012) and EMBASE (Ovid SP) (1988 to August 2012). We originally handsearched six journals (Anesthesia and Analgesia, Anesthesiology, Annals of Surgery, British Journal of Anaesthesia, Journal of Thoracic and Cardiovascular Surgery, and Journal of Vascular Surgery) (1985 to 2004). However, because these journals are properly indexed in MEDLINE, we decided to rely on electronic searches only without handsearching the journals from 2004 onwards.

SELECTION CRITERIA

We selected all randomized controlled trials in adults undergoing surgery for which a treatment measure was used for the purpose of providing renal protection during the perioperative period.

DATA COLLECTION AND ANALYSIS

We selected 72 studies for inclusion in this review. Two review authors extracted data from all selected studies and entered them into RevMan 5.1; then the data were appropriately analysed. We performed subgroup analyses for type of intervention, type of surgical procedure and pre-existing renal dysfunction. We undertook sensitivity analyses for studies with high and moderately good methodological quality.

MAIN RESULTS

The updated review included data from 72 studies, comprising a total of 4378 participants. Of these, 2291 received some form of treatment and 2087 acted as controls. The interventions consisted most often of different pharmaceutical agents, such as dopamine and its analogues, diuretics, calcium channel blockers, ACE inhibitors, NAC, ANP, sodium bicarbonate, antioxidants and EPO or selected hydration fluids. Some clinical heterogeneity and varying risk of bias were noted amongst the studies, although we were able to meaningfully interpret the data. Results showed significant heterogeneity and indicated that most interventions provided no benefit.Data on perioperative mortality were reported in 41 studies and data on acute renal injury in 44 studies (all interventions combined). Because of considerable clinical heterogeneity (different clinical scenarios, as well as considerable methodological variability amongst the studies), we did not perform a meta-analysis on the combined data.Subgroup analysis of major interventions and surgical procedures showed no significant influence of interventions on reported mortality and acute renal injury. For the subgroup of participants who had pre-existing renal damage, the risk of mortality from 10 trials (959 participants) was estimated as odds ratio (OR) 0.76, 95% confidence interval (CI) 0.38 to 1.52; the risk of acute renal injury (as reported in the trials) was estimated from 11 trials (979 participants) as OR 0.43, 95% CI 0.23 to 0.80. Subgroup analysis of studies that were rated as having low risk of bias revealed that 19 studies reported mortality numbers (1604 participants); OR was 1.01, 95% CI 0.54 to 1.90. Fifteen studies reported data on acute renal injury (criteria chosen by the individual studies; 1600 participants); OR was 1.03, 95% CI 0.54 to 1.97.

AUTHORS' CONCLUSIONS: No reliable evidence from the available literature suggests that interventions during surgery can protect the kidneys from damage. However, the criteria used to diagnose acute renal damage varied in many of the older studies selected for inclusion in this review, many of which suffered from poor methodological quality such as insufficient participant numbers and poor definitions of end points such as acute renal failure and acute renal injury. Recent methods of detecting renal damage such as the use of specific biomarkers and better defined criteria for identifying renal damage (RIFLE (risk, injury, failure, loss of kidney function and end-stage renal failure) or AKI (acute kidney injury)) may have to be explored further to determine any possible benefit derived from interventions used to protect the kidneys during the perioperative period.

摘要

背景

已采用多种方法试图保护手术患者的肾功能。这些方法最常包括药物干预,如多巴胺及其类似物、利尿剂、钙通道阻滞剂、血管紧张素转换酶(ACE)抑制剂、N - 乙酰半胱氨酸(NAC)、心房利钠肽(ANP)、碳酸氢钠、抗氧化剂和促红细胞生成素(EPO)。

目的

本综述旨在确定围手术期为保护患者肾脏所倡导的各种措施的有效性。我们考虑了以下问题:(1)围手术期是否有已知的保护肾功能的特定措施?(2)在围手术期用于保护肾脏的措施中,是否有一种方法比其他方法更有效?(3)在围手术期用于保护肾脏的措施中,是否有一种方法比其他方法更安全?

检索方法

在本次更新的综述中,我们检索了Cochrane对照试验中心注册库(CENTRAL)(《Cochrane图书馆》,2012年第2期)、MEDLINE(Ovid SP)(1966年至2012年8月)和EMBASE(Ovid SP)(1988年至2012年8月)。我们最初手工检索了六种期刊(《麻醉与镇痛》《麻醉学》《外科学年鉴》《英国麻醉学杂志》《胸心血管外科杂志》和《血管外科学杂志》)(1985年至2004年)。然而,由于这些期刊已在MEDLINE中妥善索引,我们决定从2004年起仅依靠电子检索,不再手工检索这些期刊。

选择标准

我们选择了所有对接受手术的成年人进行的随机对照试验,这些试验使用了一种治疗措施以在围手术期提供肾脏保护。

数据收集与分析

我们选择了72项研究纳入本综述。两位综述作者从所有选定的研究中提取数据,并将其录入RevMan 5.1;然后对数据进行了适当分析。我们对干预类型、手术类型和术前存在的肾功能不全进行了亚组分析。我们对方法学质量高和中等良好的研究进行了敏感性分析。

主要结果

本次更新的综述纳入了72项研究的数据,共4378名参与者。其中,2291名接受了某种形式的治疗,2087名作为对照。干预措施最常包括不同的药物制剂,如多巴胺及其类似物、利尿剂、钙通道阻滞剂、ACE抑制剂、NAC、ANP、碳酸氢钠、抗氧化剂和EPO或选定的补液。尽管我们能够有意义地解释数据,但研究中仍存在一些临床异质性和不同程度的偏倚风险。结果显示存在显著异质性,表明大多数干预措施并无益处。41项研究报告了围手术期死亡率数据,44项研究报告了急性肾损伤数据(所有干预措施合并)。由于存在相当大的临床异质性(不同的临床情况,以及研究之间相当大的方法学变异性),我们未对合并数据进行荟萃分析。主要干预措施和手术的亚组分析表明,干预措施对报告的死亡率和急性肾损伤无显著影响。对于术前已存在肾损害的参与者亚组,10项试验(959名参与者)的死亡风险估计为比值比(OR)0.76,95%置信区间(CI)0.

相似文献

1
Interventions for protecting renal function in the perioperative period.围手术期保护肾功能的干预措施。
Cochrane Database Syst Rev. 2013 Sep 11;2013(9):CD003590. doi: 10.1002/14651858.CD003590.pub4.
2
Interventions for protecting renal function in the perioperative period.围手术期保护肾功能的干预措施。
Cochrane Database Syst Rev. 2008 Oct 8(4):CD003590. doi: 10.1002/14651858.CD003590.pub3.
3
Interventions for protecting renal function in the perioperative period.围手术期保护肾功能的干预措施。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003590. doi: 10.1002/14651858.CD003590.pub2.
4
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults.用于预防成人围手术期意外低温引起并发症的主动体表升温系统。
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD009016. doi: 10.1002/14651858.CD009016.pub2.
7
Nitrates for the prevention of cardiac morbidity and mortality in patients undergoing non-cardiac surgery.硝酸盐类药物用于预防非心脏手术患者的心脏发病率和死亡率。
Cochrane Database Syst Rev. 2016 Aug 4;2016(8):CD010726. doi: 10.1002/14651858.CD010726.pub2.
8
Intravenous versus inhalational maintenance of anaesthesia for postoperative cognitive outcomes in elderly people undergoing non-cardiac surgery.非心脏手术老年患者术后认知结局:静脉麻醉维持与吸入麻醉维持的比较
Cochrane Database Syst Rev. 2018 Aug 21;8(8):CD012317. doi: 10.1002/14651858.CD012317.pub2.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
Exercise rehabilitation following intensive care unit discharge for recovery from critical illness.重症监护病房出院后进行运动康复以促进危重症恢复。
Cochrane Database Syst Rev. 2015 Jun 22;2015(6):CD008632. doi: 10.1002/14651858.CD008632.pub2.

引用本文的文献

1
Risk factors for acute kidney injury following radical cystectomy: a systematic review and meta-analysis.根治性膀胱切除术后急性肾损伤的危险因素:一项系统评价和荟萃分析。
Int J Surg. 2025 Sep 1;111(9):6330-6342. doi: 10.1097/JS9.0000000000002537. Epub 2025 Jul 14.
2
2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery.2024年欧洲心胸外科学会/欧洲成人先天性心脏病协会/欧洲心脏麻醉与围术期学会成人心脏手术体外循环指南。
Br J Anaesth. 2025 Apr;134(4):917-1008. doi: 10.1016/j.bja.2025.01.015. Epub 2025 Feb 14.
3
2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery.2024年欧洲心胸外科医师协会/欧洲心胸麻醉学会/欧洲体外循环学会成人心脏手术体外循环指南。
Eur J Cardiothorac Surg. 2025 Feb 4;67(2). doi: 10.1093/ejcts/ezae354.
4
2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery.2024年欧洲心胸外科医师协会/欧洲心胸麻醉学会/欧洲体外循环学会成人心脏手术体外循环指南。
Interdiscip Cardiovasc Thorac Surg. 2025 Feb 5;40(2). doi: 10.1093/icvts/ivaf002.
5
Fenoldopam for preventing and treating acute kidney injury.芬诺多泮预防和治疗急性肾损伤。
Cochrane Database Syst Rev. 2024 Nov 28;11(11):CD012905. doi: 10.1002/14651858.CD012905.pub2.
6
Optimizing kidney health following pediatric liver transplantation: current challenges and future directions.优化小儿肝移植后的肾脏健康:当前挑战与未来方向。
Pediatr Nephrol. 2025 Mar;40(3):605-609. doi: 10.1007/s00467-024-06606-z. Epub 2024 Nov 25.
7
Impact of spinal or epidural anaesthesia on perioperative outcomes in adult noncardiac surgery: a narrative review of recent evidence.椎管内麻醉对成人非心脏手术围手术期结局的影响:近期证据的叙述性综述。
Br J Anaesth. 2024 Aug;133(2):380-399. doi: 10.1016/j.bja.2024.04.044. Epub 2024 May 28.
8
Transcatheter Aortic Valve Implantation Access Sites: Same Goals, Distinct Aspects, Various Merits and Demerits.经导管主动脉瓣植入术的入路部位:相同目标、不同方面、诸多优缺点
J Cardiovasc Dev Dis. 2023 Dec 22;11(1):4. doi: 10.3390/jcdd11010004.
9
The correlation of intraoperative oliguria with acute kidney injury after noncardiac surgery: a systematic review and meta-analysis.术中少尿与非心脏手术后急性肾损伤的相关性:系统评价和荟萃分析。
Int J Surg. 2023 Mar 1;109(3):449-457. doi: 10.1097/JS9.0000000000000284.
10
Association Between the Presence of Pulmonary Hypertension Before Cardiovascular Surgery and the Nephroprotective Effect of Carperitide: A Retrospective Cohort Study.心血管手术前肺动脉高压的存在与卡培立肽的肾保护作用之间的关联:一项回顾性队列研究
Cureus. 2022 Mar 6;14(3):e22891. doi: 10.7759/cureus.22891. eCollection 2022 Mar.

本文引用的文献

1
The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review.急性肾损伤的RIFLE和AKIN分类:一项批判性和全面性综述。
Clin Kidney J. 2013 Feb;6(1):8-14. doi: 10.1093/ckj/sfs160. Epub 2012 Jan 1.
2
Multicenter trial of carperitide in patients with renal dysfunction undergoing cardiovascular surgery.卡培立肽用于肾功能不全的心血管手术患者的多中心试验。
Gen Thorac Cardiovasc Surg. 2012 Jan;60(1):21-30. doi: 10.1007/s11748-011-0846-5. Epub 2012 Jan 13.
3
Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery.短期阿托伐他汀预防心脏手术后急性肾损伤的双盲、随机对照试验。
Nephrology (Carlton). 2012 Mar;17(3):215-24. doi: 10.1111/j.1440-1797.2011.01546.x.
4
Erythropoietin (EPO) in acute kidney injury.促红细胞生成素(EPO)在急性肾损伤中的作用。
Ann Intensive Care. 2011 Mar 21;1(1):3. doi: 10.1186/2110-5820-1-3.
5
Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD.低剂量人心房利钠肽输注在非透析慢性肾脏病行冠状动脉旁路移植术患者中的结果:NU-HIT(日本大学低剂量 HANP 输注治疗心脏手术期间 CKD 工作组研究)试验。
J Am Coll Cardiol. 2011 Aug 23;58(9):897-903. doi: 10.1016/j.jacc.2011.03.056.
6
Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function.通过对损伤持续时间和基线肾功能进行分层,改善了危重病患者急性肾损伤尿液生物标志物的性能。
Kidney Int. 2011 May;79(10):1119-30. doi: 10.1038/ki.2010.555. Epub 2011 Feb 9.
7
N-acetylcysteine does not prevent renal dysfunction after off-pump coronary artery bypass surgery.N-乙酰半胱氨酸不能预防不停跳冠状动脉旁路手术后的肾功能障碍。
Eur J Anaesthesiol. 2010 Nov;27(11):973-7. doi: 10.1097/EJA.0b013e3283383506.
8
Intraoperative fluid replacement and postoperative creatine phosphokinase levels in laparoscopic bariatric patients.腹腔镜减重手术患者术中液体置换与术后肌酸磷酸激酶水平。
Obes Surg. 2010 Jun;20(6):698-701. doi: 10.1007/s11695-010-0092-4. Epub 2010 Mar 3.
9
Furosemide infusion prevents the requirement of renal replacement therapy after cardiac surgery.静脉输注呋塞米可避免心脏手术后进行肾脏替代治疗。
Anadolu Kardiyol Derg. 2009 Dec;9(6):499-504.
10
Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study.心脏手术期间持续输注低剂量人心房利钠肽对肾功能的影响:一项随机对照研究。
J Am Coll Cardiol. 2009 Sep 15;54(12):1058-64. doi: 10.1016/j.jacc.2009.05.047.